Rare disease drug Vimizim gets NICE 'yes' – but needs real-world data

3rd September 2015

Rare disease drug Vimizim gets NICE 'yes' – but needs real-world dataAndrew McConaghie

NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McConaghie.The... Read more

Bayer and Alnylam drugs among highlights at ESC

2nd September 2015

Bayer and Alnylam drugs among highlights at ESCKevin Grogan

New drug candidates in heart failure and cholesterol control, plus insights into healthy lifestyle habits, are among the highlights from the London conference, writes Kevin Grogan.The almost 33,000 delegates who... Read more

Doctors are drowning in guidelines: ‘social learning’ a lifeline

2nd September 2015

Doctors are drowning in guidelines: ‘social learning’ a lifelineJames Quekett

Dr James Quekett says doctors are struggling to keep up with guidelines, and can learn from online peer conversations. Pharma can join the conversation too – but must understand the... Read more

Challenges of ageing for people with HIV

1st September 2015

Challenges of ageing for people with HIVDavid Rowlands

David Rowlands examines the complex issues faced by the growing numbers of older people living with HIV today and what services they need to help them improve their quality of... Read more


Amgen to sell Repatha in Europe at steep discount to US

3rd September 2015

Amgen to sell Repatha in Europe at steep discount to USPhil Taylor

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on... Read more

Valeant buys stake in AZ's psoriasis antibody

2nd September 2015

Valeant buys stake in AZ's psoriasis antibodyPhil Taylor

Valeant's policy of growth by acquisition shows no signs of slowing down, with the Canadian firm agreeing a $345 million deal to buy a stake in AstraZeneca's (AZ) psoriasis candidate... Read more

BMS extends fibrosis focus with $1.25bn Promedior deal

1st September 2015

BMS extends fibrosis focus with $1.25bn Promedior dealPhil Taylor

Bristol-Myers Squibb (BMS) has been steadily building its position in fibrotic diseases for some time, but accelerated its efforts this week with a $1.25 billion deal giving it the right... Read more

Sanofi and Google to collaborate on diabetes

1st September 2015

Sanofi and Google to collaborate on diabetesAndrew McConaghie

A new alliance between Sanofi and Google has been launched to improve care in people with type 1 and type 2 diabetes, the latest in a growing number of tie-ups... Read more

Audio & Video

Live webinar: Accelerate the success of…

Zephyr data strategy webinar-new


Join this webinar to hear case studies and key success factors in using global heath data and market insights... View more

Available on demand: Changing behaviour:…

BrightTALK holding slide 4 22June


Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…



Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

White Papers

Successful biopharma product launches de…

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovationChristian Marcazzo & Robin Munro

A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity of healthcare data available today – particularly that presented by real-world data.View info

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Further News & Articles

Value model sets low price for Lilly's necitumumab

With many new cancer drugs now costing $100,000 a year or more, US researchers have developed a model that works... Read more


World’s biggest cardiology congress comes to London

The world's biggest cardiology congress kicks off in London on Saturday, with academics, heart specialists and p... Read more


Fragile X therapy tackles underlying mechanism

A potential therapy for rare disease Fragile X syndrome – one of the leading genetic causes of autism – is on its... Read more


Novo Nordisk splashes out as oral semaglutide starts phase III

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 dia... Read more


Pharma gets social: Ten tweet chats transforming pharma digital engagement

Daniel Ghinn highlights why tweet chats are increasingly popular in the healthcare space.

The pas... Read more


NICE says 'yes' to new anticoagulant Lixiana

Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment... Read more